iTeos Therapeutics, Inc. Expected to Post FY2027 Earnings of ($6.43) Per Share (NASDAQ:ITOS)

iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) – Analysts at Wedbush issued their FY2027 earnings per share estimates for iTeos Therapeutics in a research report issued to clients and investors on Wednesday, March 15th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($6.43) for the year. Wedbush currently has a “Outperform” rating and a $33.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($4.30) per share.

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their price objective on iTeos Therapeutics from $34.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $54.00 price target on shares of iTeos Therapeutics in a report on Friday.

iTeos Therapeutics Stock Performance

Shares of ITOS stock opened at $14.12 on Friday. The stock’s 50-day moving average is $18.81 and its two-hundred day moving average is $19.42. The firm has a market cap of $502.39 million, a price-to-earnings ratio of 2.05 and a beta of 1.42. iTeos Therapeutics has a 1 year low of $13.81 and a 1 year high of $37.26.

Hedge Funds Weigh In On iTeos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd purchased a new position in shares of iTeos Therapeutics during the first quarter worth about $67,000. Quantbot Technologies LP acquired a new stake in iTeos Therapeutics in the second quarter valued at about $69,000. Mutual of America Capital Management LLC lifted its position in iTeos Therapeutics by 17.4% in the second quarter. Mutual of America Capital Management LLC now owns 3,402 shares of the company’s stock valued at $70,000 after purchasing an additional 505 shares during the period. Ensign Peak Advisors Inc acquired a new stake in iTeos Therapeutics in the first quarter valued at about $73,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in iTeos Therapeutics in the third quarter valued at about $117,000.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

See Also

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with's FREE daily email newsletter.